Last 7 days
-11.5%
Last 30 days
-13.5%
Last 90 days
-12.1%
Trailing 12 Months
-26.0%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABBV | 280.3B | 58.1B | 3.63% | 0.47% | 23.68 | 4.83 | 3.30% | 2.55% |
REGN | 88.4B | 12.2B | 9.24% | 19.26% | 20.38 | 7.26 | -24.26% | -46.28% |
VRTX | 80.5B | 8.9B | 9.01% | 22.50% | 24.24 | 9.01 | 17.91% | 41.84% |
INCY | 15.7B | 3.4B | -8.71% | -10.94% | 45.97 | 4.61 | 13.67% | -64.09% |
MID-CAP | ||||||||
NTRA | 6.0B | 820.2M | 13.45% | 34.53% | -11 | 7.34 | 31.13% | -16.13% |
ARWR | 2.6B | 278.3M | -25.65% | -45.82% | -16.66 | 9.25 | 92.72% | 15.56% |
SMALL-CAP | ||||||||
VCYT | 1.5B | 296.5M | -13.46% | -26.05% | -40.51 | 4.99 | 35.09% | 51.62% |
CSTL | 589.5M | 137.0M | -8.87% | -47.72% | -8.78 | 4.3 | 45.65% | -114.55% |
CDNA | 472.7M | 321.8M | -38.89% | -76.73% | -6.17 | 1.47 | 8.57% | -149.86% |
NVTA | 294.7M | 516.3M | -38.46% | -85.15% | -0.09 | 0.57 | 12.13% | -719.59% |
ORGO | 252.0M | 450.9M | -19.46% | -73.63% | 16.23 | 0.56 | -3.52% | -83.51% |
CELC | 155.1M | - | -11.28% | 26.74% | -4.36 | - | - | -39.92% |
OPGN | 3.5M | 3.3M | 41.75% | 90.10% | -0.11 | 1.07 | -21.77% | 4.40% |
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | 4.6% | 296,536,000 | 283,575,000 | 268,353,000 | 250,594,000 | 219,514,000 |
S&GA Expenses | 2.0% | 97,560,000 | 95,645,000 | 91,637,000 | 87,298,000 | 79,840,000 |
R&D Expenses | 2.6% | 40,603,000 | 39,568,000 | 36,801,000 | 33,673,000 | 29,843,000 |
Costs and Expenses | 1.8% | 337,617,000 | 331,569,000 | 323,348,000 | 302,330,000 | 301,417,000 |
EBITDA | 43.5% | -10,463,000 | -18,527,000 | -25,423,000 | -26,846,000 | - |
EBITDA Margin | 46.0% | -0.04 | -0.07 | -0.09 | -0.11 | - |
Earnings Before Taxes | 17.8% | -36,400,000 | -44,303,000 | -50,907,000 | -50,450,000 | -81,649,000 |
EBT Margin | 21.4% | -0.12 | -0.16 | -0.19 | -0.20 | - |
Interest Expenses | Infinity% | 9,000 | 0.00 | 0.00 | 63,000 | 9,000 |
Net Income | 15.5% | -36,560,000 | -43,244,000 | -48,650,000 | -48,156,000 | -75,563,000 |
Net Income Margin | 19.2% | -0.12 | -0.15 | -0.18 | -0.19 | - |
Free Cahsflow | 20.8% | -1,014,000 | -1,281,000 | -9,798,000 | -6,565,000 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 2.7% | 1,156 | 1,126 | 1,144 | 1,174 | 1,188 |
Current Assets | 4.2% | 249 | 239 | 235 | 238 | 243 |
Cash Equivalents | -8.9% | 155 | 170 | 153 | 164 | 173 |
Inventory | 3.6% | 14.00 | 14.00 | 15.00 | 12.00 | 11.00 |
Goodwill | 2.8% | 696 | 677 | 690 | 704 | 708 |
Liabilities | 4.4% | 81.00 | 78.00 | 80.00 | 88.00 | 91.00 |
Current Liabilities | 7.3% | 63.00 | 58.00 | 59.00 | 63.00 | 64.00 |
LT Debt, Current | -100.0% | - | 1.00 | 1.00 | 1.00 | 1.00 |
LT Debt, Non Current | - | - | - | - | - | - |
Shareholder's Equity | 2.6% | 1,075 | 1,048 | 1,064 | 1,085 | 1,097 |
Retained Earnings | -1.0% | -393 | -389 | -381 | -371 | -357 |
Additional Paid-In Capital | 0.5% | 1,500 | 1,492 | 1,483 | 1,477 | 1,469 |
Accumulated Depreciation | - | 21.00 | - | - | - | - |
Shares Outstanding | 0.3% | 72.00 | 72.00 | 72.00 | 71.00 | 71.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | 20.8% | 8.00 | 6.00 | -2.18 | 0.00 | -31.62 |
Share Based Compensation | 0.5% | 27.00 | 27.00 | 27.00 | 25.00 | 23.00 |
Cashflow From Investing | -1044.4% | -29.39 | -2.57 | -176 | -166 | -739 |
Cashflow From Financing | -2.2% | 3.00 | 4.00 | 5.00 | 7.00 | 596 |
100%
70.4%
48.1%
Y-axis is the maximum loss one would have experienced if Veracyte was unfortunately bought at previous high price.
21.1%
29.9%
-3.9%
FIve years rolling returns for Veracyte.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-23 | MetLife Investment Management, LLC | unchanged | - | 270,584 | 900,554 | 0.01% |
2023-03-17 | American Portfolios Advisors | added | 0.59 | -28,064 | 146,379 | 0.01% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | sold off | -100 | -729,000 | - | -% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -83.58 | -5,000 | 1,000 | -% |
2023-02-28 | Voya Investment Management LLC | reduced | -82.58 | -1,965,230 | 651,768 | -% |
2023-02-24 | SRS Capital Advisors, Inc. | new | - | 570 | 570 | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | new | - | 515,000 | 515,000 | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | added | 0.2 | 6,778 | 23,778 | -% |
2023-02-21 | MACQUARIE GROUP LTD | sold off | -100 | -4,350,000 | - | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | unchanged | - | 871 | 2,871 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | william blair investment management, llc | 0.8% | 558,384 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.55% | 6,852,657 | SC 13G/A | |
Feb 06, 2023 | state street corp | 5.80% | 4,159,331 | SC 13G | |
Feb 06, 2023 | wellington management group llp | 9.25% | 6,636,543 | SC 13G/A | |
Jan 25, 2023 | blackrock inc. | 9.1% | 6,534,569 | SC 13G/A | |
Feb 14, 2022 | nikko asset management americas, inc. | 4.39% | 3,121,103 | SC 13G/A | |
Feb 10, 2022 | invesco ltd. | 5.8% | 4,114,031 | SC 13G/A | |
Feb 09, 2022 | ark investment management llc | 11.57% | 8,222,281 | SC 13G/A | |
Feb 04, 2022 | artisan partners limited partnership | 7.0% | 4,956,409 | SC 13G/A | |
Feb 04, 2022 | wellington management group llp | 7.15% | 5,078,827 | SC 13G |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 4.49 -78.18% | 5.39 -73.81% | 7.74 -62.39% | 10.91 -46.99% | 21.36 3.79% |
Current Inflation | 4.43 -78.47% | 5.23 -74.59% | 7.28 -64.63% | 10.00 -51.41% | 18.93 -8.02% |
Very High Inflation | 4.35 -78.86% | 5.04 -75.51% | 6.73 -67.30% | 8.94 -56.56% | 16.11 -21.72% |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 17, 2023 | 4 | Insider Trading | |
Mar 16, 2023 | 4 | Insider Trading | |
Mar 15, 2023 | 144 | Notice of Insider Sale Intent | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 09, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading | |
Mar 03, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-16 | EASTHAM KARIN | acquired | 227,250 | 12.12 | 18,750 | - |
2023-03-16 | EASTHAM KARIN | sold | -427,044 | 22.7757 | -18,750 | - |
2023-03-15 | Anderson Bonnie H | acquired | 190,740 | 5.61 | 34,000 | - |
2023-03-15 | Anderson Bonnie H | sold | -773,888 | 22.7614 | -34,000 | - |
2023-03-06 | Stapley Marc | acquired | - | - | 78,044 | chief executive officer |
2023-03-06 | Chambers Rebecca | acquired | - | - | 26,014 | chief financial officer |
2023-03-06 | McGuire Annie | acquired | - | - | 23,413 | svp, general counsel |
2023-03-06 | Wygant Jonathan | acquired | - | - | 8,868 | vp, chief accounting officer |
2023-03-02 | Wygant Jonathan | sold (taxes) | -29,498 | 24.1 | -1,224 | vp, chief accounting officer |
2023-03-02 | Chambers Rebecca | sold (taxes) | -65,696 | 24.1 | -2,726 | chief financial officer |
Consolidated Statements of Operations - USD ($) | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Revenue: | |||
Total revenue | $ 296,536,000 | $ 219,514,000 | $ 117,483,000 |
Operating expenses: | |||
Research and development | 40,603,000 | 29,843,000 | 17,204,000 |
Selling and marketing | 97,560,000 | 79,840,000 | 52,389,000 |
General and administrative | 76,518,000 | 101,353,000 | 36,729,000 |
Intangible asset amortization | 21,354,000 | 15,981,000 | 5,095,000 |
Total operating expenses | 337,617,000 | 301,417,000 | 152,872,000 |
Loss from operations | (41,081,000) | (81,903,000) | (35,389,000) |
Other income, net | 4,654,000 | 254,000 | 480,000 |
Loss before income tax benefit | (36,427,000) | (81,649,000) | (34,909,000) |
Income tax provision (benefit) | 133,000 | (6,086,000) | 0 |
Net loss | $ (36,560,000) | $ (75,563,000) | $ (34,909,000) |
Net loss per common share, basic (in USD per share) | $ (0.51) | $ (1.11) | $ (0.66) |
Net loss per common share, diluted (in USD per share) | $ (0.51) | $ (1.11) | $ (0.66) |
Shares use to compute net loss per common share, basic (in shares) | 71,549,204 | 67,890,328 | 53,239,231 |
Shares use to compute net loss per common share, diluted (in shares) | 71,549,204 | 67,890,328 | 53,239,231 |
Testing revenue | |||
Revenue: | |||
Total revenue | $ 250,544,000 | $ 188,182,000 | $ 101,970,000 |
Operating expenses: | |||
Cost of revenue | 75,317,000 | 58,860,000 | 35,913,000 |
Product revenue | |||
Revenue: | |||
Total revenue | 12,632,000 | 11,464,000 | 9,845,000 |
Operating expenses: | |||
Cost of revenue | 7,820,000 | 5,887,000 | 4,921,000 |
Biopharmaceutical and other revenue | |||
Revenue: | |||
Total revenue | 33,360,000 | 19,868,000 | 5,668,000 |
Operating expenses: | |||
Cost of revenue | $ 18,445,000 | $ 9,653,000 | $ 621,000 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 154,247 | $ 173,197 |
Short-term investments | 24,605 | 3,964 |
Accounts receivable | 44,021 | 41,461 |
Supplies and inventory | 14,294 | 11,225 |
Prepaid expenses and other current assets | 11,469 | 13,255 |
Total current assets | 248,636 | 243,102 |
Property and equipment, net | 17,702 | 15,098 |
Right-of-use assets - operating leases | 13,160 | 16,043 |
Intangible assets, net | 174,866 | 202,731 |
Goodwill | 695,891 | 707,904 |
Restricted cash | 749 | 749 |
Other assets | 5,418 | 2,198 |
Total assets | 1,156,422 | 1,187,825 |
Current liabilities: | ||
Accounts payable | 11,911 | 12,360 |
Accrued liabilities | 37,774 | 39,475 |
Current portion of long-term debt | 0 | 1,127 |
Current portion of deferred revenue | 2,613 | 4,646 |
Current portion of acquisition-related contingent consideration | 6,060 | 2,682 |
Current portion of operating lease liabilities | 4,070 | 3,630 |
Current portion of other liabilities | 186 | 231 |
Total current liabilities | 62,614 | 64,151 |
Deferred revenue, net of current portion | 0 | 343 |
Deferred tax liability | 4,531 | 5,592 |
Acquisition-related contingent consideration, net of current portion | 2,498 | 5,722 |
Operating lease liabilities, net of current portion | 10,648 | 14,096 |
Other liabilities | 931 | 1,407 |
Total liabilities | 81,222 | 91,311 |
Commitments and contingencies | ||
Stockholders' equity: | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of December 31, 2022 and 2021 | 0 | 0 |
Common stock, $0.001 par value; 125,000,000 shares authorized, 71,959,454 and 71,123,108 shares issued and outstanding as of December 31, 2022 and 2021, respectively | 72 | 71 |
Additional paid-in capital | 1,500,191 | 1,468,683 |
Accumulated deficit | (393,717) | (357,157) |
Accumulated other comprehensive loss | (31,346) | (15,083) |
Total stockholders' equity | 1,075,200 | 1,096,514 |
Total liabilities and stockholders' equity | $ 1,156,422 | $ 1,187,825 |